Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Purpose of Review Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care. Recent Findings ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape. Summary ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.